BiomX (PHGE) Non-Current Assets (2018 - 2026)
BiomX's (PHGE) quarterly Non-Current Assets came in at $25.8 million in Q2 2026, up 20.34% year-over-year from $21.4 million in Q2 2025, and up 12289.42% quarter-over-quarter from $208000.0 in Q1 2026.
Analysis
BiomX (PHGE) Non-Current Assets (2018 - 2026) Analysis & Trends
BiomX has disclosed Non-Current Assets across 9 years of filings, most recently posting $25.8 million for Q2 2026.
- In Q2 2026, Non-Current Assets rose 20.34% year-over-year to $25.8 million; the TTM figure through Jun 2026 stood at $25.8 million (up 20.34% YoY), while the FY2025 annual figure was $208000.0, down 99.08% from the prior year.
- Non-Current Assets came in at $25.8 million for Q2 2026 at BiomX, up from $208000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $33.5 million in Q2 2024 to a low of $208000.0 in Q4 2025.
- Average Non-Current Assets over 5 years is $14.4 million, with a median of $10.1 million recorded in 2022.
- Year-over-year, Non-Current Assets surged 315.95% in 2024 and sank 99.08% in 2025.
- Over 5 years, Non-Current Assets stood at $8.6 million in 2022, then declined by 14.49% to $7.4 million in 2023, then surged by 207.06% to $22.7 million in 2024, then tumbled by 99.08% to $208000.0 in 2025, then jumped by 12289.42% to $25.8 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $25.8 million in Q2 2026, $208000.0 in Q1 2026, and $208000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 468.65 Mn |
| 10 | BiomX | 1.55 Mn | 7.73 Mn | 97,000.00 | 25.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.77 Mn |
| Mar 31, 2026 | 208,000.00 |
| Dec 31, 2025 | 208,000.00 |
| Sep 30, 2025 | 17.31 Mn |
| Jun 30, 2025 | 21.42 Mn |
| Mar 31, 2025 | 22.12 Mn |
| Dec 31, 2024 | 22.71 Mn |
| Sep 30, 2024 | 31.66 Mn |
| Jun 30, 2024 | 33.54 Mn |
| Dec 31, 2023 | 7.40 Mn |
| Sep 30, 2023 | 7.76 Mn |
| Jun 30, 2023 | 8.06 Mn |
| Mar 31, 2023 | 8.47 Mn |
| Dec 31, 2022 | 8.65 Mn |
| Sep 30, 2022 | 9.37 Mn |
| Jun 30, 2022 | 10.07 Mn |
| Mar 31, 2022 | 10.64 Mn |
| Dec 31, 2021 | 11.35 Mn |
| Sep 30, 2021 | 12.00 Mn |
| Jun 30, 2021 | 11.81 Mn |